Respiratory Cancers

Australasian malignant pleural effusion trial-2

Australasian malignant pleural effusion (AMPLE) trial-2

Malignant pleural effusions (MPE) can complicate most cancers, causing dyspnea and impairment in quality of life (QoL).

Indwelling pleural catheters (IPC) are a novel management approach allowing ambulatory fluid drainage, fewer invasive procedures and reduced hospitalizations than conventional talc pleurodesis.

Clinicians at the Institute for Respiratory Health lead the Australasian Malignant PLeural Effusion (AMPLE) trial-2 study.

Patients with MPEs will be randomized 1:1 to either aggressive (daily) or symptom-guided drainage regimes after IPC insertion, with the aim to determine which regime is superior in improving clinical outcomes.

The study is a a multi-centre, open-labeled, randomized trial and the primary outcome is the mean daily dyspnea score, measured by a 100mm visual analogue scale (VAS), over the first 60 days. Secondary outcomes include benefits on activity levels, complications, hospital days, health costs, and QoL measures.

To get involved or for more information, contact the Research Leader.

Australasian malignant pleural effusion trial-2 was last modified: May 12th, 2016 by Sarah Cermak

Research Leaders

Prof Gary Lee

MBChB, PhD, FRACP, FRCP, FCCP

Head of Pleural Medicine Group

gary.lee@health.wa.gov.au
LinkedIn

Prof Gary Lee was last modified: February 24th, 2017 by Sarah Cermak

Australasian malignant pleural effusion trial-2 was last modified: May 12th, 2016 by Sarah Cermak